Bimekizumab to Benefit Psoriatic Arthritis Patients According to the Phase III Clinical Trial Results
EULAR 2022: Bimekizumab to Benefit Psoriatic Arthritis
Bimekizumab in patients with active Psoriatic arthritis and an inadequate response to tumor necrosis factor inhibitors: 16-week efficacy and safety from BE COMPLETE, a Phase III, multicenter, randomized, placebo-controlled study (Abstract # OP0255).
Bimekizumab is a monoclonal IgG1 antibody that suppresses interleukin (IL)-17F and IL-17A in a specific manner. BE COMPLETE, a major Phase III trial compared the effectiveness and safety of bimekizumab to placebo in patients with active PsA with a previous unsatisfactory TNFi response.
At Week 16, the primary endpoint (ACR50) was met, as were all ranked secondary objectives (HAQ-DI CfB, PASI90, SF-36 PCS CfB, and MDA response). Bimekizumab patients had 43.4 percent ACR50 response rates compared to 6.8 percent for placebo patients. 40.1 percent of bimekizumab participants and 33.3 percent of placebo participants experienced treatment-emergent adverse events (TEAEs). The most prevalent TEAEs were fungus infections, nasopharyngitis, oral candidiasis, and upper respiratory tract infection, which affected 4.5 percent, 3.7 percent, 2.6 percent, and 2.2 percent of bimekizumab patients, respectively. Bimekizumab had an excellent safety and tolerability profile overall.
KOL Insights
Bimekizumab, a dual IL-17A, and IL-17F inhibitor have a bright future in the treatment of active psoriatic arthritis, according to the findings of the BE COMPLETE trial. This persistent and painful illness can have a major impact on a patient's life. The goal of treatment is to reduce disease activity to the bare minimum, which can enhance the quality of life of patients suffering from psoriatic arthritis.
Conclusion
The BE COMPLETE Phase III study met all its primary and secondary endpoints. Patients who were treated with bimekizumab exhibited improvements in joints, skin, and HRQoL-related outcomes in Week-16, compared to the ones who were treated with placebo.
Bimekizumab treatment improved the composite outcome of minimum disease activity as well, suggesting the efficacy of dual inhibition throughout PsA disease symptoms. The study's safety and tolerability profile were in line with previous studies, indicating that it has the potential to treat this chronic illness.
Because the regulatory application for bimekizumab in PsA is due this year, it is believed that these findings will play a significant role in bimekizumab's approval for this indication. If authorized, Bimekizumab is expected to provide stiff competition in the present PsA market.
For more detailed information visit: https://www.delveinsight.com/eular-conference/eular-2022
Some of the Latest Abstracts launched in EULAR 2022:
Report Offerings by DelveInsight:
Diagnostic Imaging Equipment Market
Diagnostic Imaging Equipment Market By Product (X-Ray Imaging Systems, Computed Tomography (CT) Scanners, Ultrasound Systems, Magnetic Resonance Imaging (MRI) Systems, Nuclear Imaging Systems, Mammography Systems, And Others), By Application (Cardiology, Oncology, Gastroenterology, Gynecology, And Other Applications), By End-User (Hospitals, Diagnostic Imaging Centres, And Others), by geography is expected to grow at a steady CAGR forecast till 2026 owing to rising technological advancement and increasing prevalence of chronic diseases.
Invasive Candidiasis Market
"DelveInsight’s ‘Invasive Candidiasis Market Insight, Competitive Landscape and Market Forecast, 2027’ report delivers an in-depth understanding of Invasive Candidiasis and the historical and forecasted Invasive Candidiasis market trends, globally, which comprises North America, Europe, APAC, and RoW.
Sialidosis Market
DelveInsight's "Sialidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Sialidosis, historical and forecasted epidemiology as well as the Sialidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Filgrastim Biosimilar Insight
DelveInsight’s, “Filgrastim Biosimilar Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in the Filgrastim Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Pain Management Devices Market
Pain Management Devices Market By Type Of Devices (Neuromodulation & Neurostimulation Devices, Analgesic Infusion Pumps [Intrathecal Infusion Pumps and External Infusion Pumps], Ablation Devices [Radiofrequency Ablation Devices And Cryoablation Devices], And Others), By Application (Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, and Others), By Geography is expected to grow at a steady CAGR Forecast till 2027.
To know more about our Competitive Services, Click here: Pharma Competitive Intelligence
https://www.delveinsight.com/consulting/competitive-intelligence-services
Also, take a glance at the Blogs by DelveInsight:
Comments
Post a Comment